The Association Between Antibody Responses and Prolonged Viable Severe Acute Respiratory Syndrome Coronavirus 2 Shedding in Immunocompromised Patients: A Prospective Cohort Study.
So Yun LimJun-Won KimJi Yeun KimSung-Woon KangChoi-Young JangEuijin ChangJeong-Sun YangKyung-Chang KimHee-Chang JangDa Sol KimYounmin ShinJoo-Yeon LeeSung Han KimPublished in: The Journal of infectious diseases (2024)
Immunocompromised patients with coronavirus disease 2019 were prospectively enrolled from March to November 2022 to understand the association between antibody responses and severe acute respiratory syndrome coronavirus 2 shedding. A total of 62 patients were analyzed, and the results indicated a faster decline in genomic and subgenomic viral RNA in patients with higher neutralizing and S1-specific immunoglobulin G (IgG) antibodies (both P < .001). Notably, high neutralizing antibody levels were associated with a significantly faster decrease in viable virus cultures (P = .04). Our observations suggest the role of neutralizing antibodies in prolonged virus shedding in immunocompromised patients, highlighting the potential benefits of enhancing their humoral immune response through vaccination or monoclonal antibody treatments.
Keyphrases
- end stage renal disease
- respiratory syndrome coronavirus
- coronavirus disease
- immune response
- ejection fraction
- sars cov
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- monoclonal antibody
- inflammatory response
- dna methylation
- risk assessment
- dengue virus
- genome wide
- mechanical ventilation
- acute respiratory distress syndrome